Cargando…
Lost in translation: returning germline genetic results in genome-scale cancer research
BACKGROUND: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408494/ https://www.ncbi.nlm.nih.gov/pubmed/28454591 http://dx.doi.org/10.1186/s13073-017-0430-4 |
_version_ | 1783232319253905408 |
---|---|
author | Johns, Amber L. McKay, Skye H. Humphris, Jeremy L. Pinese, Mark Chantrill, Lorraine A. Mead, R. Scott Tucker, Katherine Andrews, Lesley Goodwin, Annabel Leonard, Conrad High, Hilda A. Nones, Katia Patch, Ann-Marie Merrett, Neil D. Pavlakis, Nick Kassahn, Karin S. Samra, Jaswinder S. Miller, David K. Chang, David K. Pajic, Marina Pearson, John V. Grimmond, Sean M. Waddell, Nicola Zeps, Nikolajs Gill, Anthony J. Biankin, Andrew V. |
author_facet | Johns, Amber L. McKay, Skye H. Humphris, Jeremy L. Pinese, Mark Chantrill, Lorraine A. Mead, R. Scott Tucker, Katherine Andrews, Lesley Goodwin, Annabel Leonard, Conrad High, Hilda A. Nones, Katia Patch, Ann-Marie Merrett, Neil D. Pavlakis, Nick Kassahn, Karin S. Samra, Jaswinder S. Miller, David K. Chang, David K. Pajic, Marina Pearson, John V. Grimmond, Sean M. Waddell, Nicola Zeps, Nikolajs Gill, Anthony J. Biankin, Andrew V. |
author_sort | Johns, Amber L. |
collection | PubMed |
description | BACKGROUND: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified; and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful for others developing their own policies. METHODS: We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic germline mutations in candidate genes (n = 130) with established predisposition to PC or medium–high penetrance genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated and classified according to international guidelines. Variants were considered actionable if clinical utility was established, with regard to prevention, diagnosis, prognostication and/or therapy. RESULTS: A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework, representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR. CONCLUSION: Returning research results within the context of large-scale genomics research is a labour-intensive, highly variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience a clinical difference as a result of returning individual results is currently low. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-017-0430-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5408494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54084942017-05-02 Lost in translation: returning germline genetic results in genome-scale cancer research Johns, Amber L. McKay, Skye H. Humphris, Jeremy L. Pinese, Mark Chantrill, Lorraine A. Mead, R. Scott Tucker, Katherine Andrews, Lesley Goodwin, Annabel Leonard, Conrad High, Hilda A. Nones, Katia Patch, Ann-Marie Merrett, Neil D. Pavlakis, Nick Kassahn, Karin S. Samra, Jaswinder S. Miller, David K. Chang, David K. Pajic, Marina Pearson, John V. Grimmond, Sean M. Waddell, Nicola Zeps, Nikolajs Gill, Anthony J. Biankin, Andrew V. Genome Med Research BACKGROUND: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified; and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful for others developing their own policies. METHODS: We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic germline mutations in candidate genes (n = 130) with established predisposition to PC or medium–high penetrance genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated and classified according to international guidelines. Variants were considered actionable if clinical utility was established, with regard to prevention, diagnosis, prognostication and/or therapy. RESULTS: A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework, representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR. CONCLUSION: Returning research results within the context of large-scale genomics research is a labour-intensive, highly variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience a clinical difference as a result of returning individual results is currently low. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-017-0430-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-28 /pmc/articles/PMC5408494/ /pubmed/28454591 http://dx.doi.org/10.1186/s13073-017-0430-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Johns, Amber L. McKay, Skye H. Humphris, Jeremy L. Pinese, Mark Chantrill, Lorraine A. Mead, R. Scott Tucker, Katherine Andrews, Lesley Goodwin, Annabel Leonard, Conrad High, Hilda A. Nones, Katia Patch, Ann-Marie Merrett, Neil D. Pavlakis, Nick Kassahn, Karin S. Samra, Jaswinder S. Miller, David K. Chang, David K. Pajic, Marina Pearson, John V. Grimmond, Sean M. Waddell, Nicola Zeps, Nikolajs Gill, Anthony J. Biankin, Andrew V. Lost in translation: returning germline genetic results in genome-scale cancer research |
title | Lost in translation: returning germline genetic results in genome-scale cancer research |
title_full | Lost in translation: returning germline genetic results in genome-scale cancer research |
title_fullStr | Lost in translation: returning germline genetic results in genome-scale cancer research |
title_full_unstemmed | Lost in translation: returning germline genetic results in genome-scale cancer research |
title_short | Lost in translation: returning germline genetic results in genome-scale cancer research |
title_sort | lost in translation: returning germline genetic results in genome-scale cancer research |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408494/ https://www.ncbi.nlm.nih.gov/pubmed/28454591 http://dx.doi.org/10.1186/s13073-017-0430-4 |
work_keys_str_mv | AT johnsamberl lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT mckayskyeh lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT humphrisjeremyl lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT pinesemark lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT chantrilllorrainea lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT meadrscott lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT tuckerkatherine lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT andrewslesley lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT goodwinannabel lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT leonardconrad lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT highhildaa lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT noneskatia lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT patchannmarie lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT merrettneild lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT pavlakisnick lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT kassahnkarins lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT samrajaswinders lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT millerdavidk lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT changdavidk lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT pajicmarina lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT pearsonjohnv lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT grimmondseanm lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT waddellnicola lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT zepsnikolajs lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT gillanthonyj lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch AT biankinandrewv lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch |